Anton Faron1, Claus C Pieper1, Frederic C Schmeel1, Alois M Sprinkart1, Daniel L R Kuetting1, Rolf Fimmers2, Jonel Trebicka3,4,5,6, Hans H Schild1, Carsten Meyer1, Daniel Thomas1, Julian A Luetkens7. 1. Department of Radiology, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. 2. Department of Medical Biometry, Informatics, and Epidemiology, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. 3. Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. 4. European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain. 5. Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. 6. Institute for Bioengineering of Catalonia, Barcelona, Spain. 7. Department of Radiology, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. julian.luetkens@ukbonn.de.
Abstract
OBJECTIVES: To investigate the clinical potential of fat-free muscle area (FFMA) to predict outcome in patients with liver-predominant metastatic colorectal cancer (mCRC) undergoing radioembolization (RE) with 90Yttrium microspheres. METHODS: Patients with mCRC who underwent RE in our center were included in this retrospective study. All patients received liver magnetic resonance imaging including standard T2-weighted images. The total erector spinae muscle area and the intramuscular adipose tissue area were measured at the level of the origin of the superior mesenteric artery and subtracted to calculate FFMA. Cutoff values for definition of low FFMA were 3644 mm2 in men and 2825 mm2 in women. The main outcome was overall survival (OS). For survival analysis, the Kaplan-Meier method and Cox regressions comparing various clinic-oncological parameters which potentially may affect OS were performed. RESULTS: Seventy-seven patients (28 female, mean age 60 ± 11 years) were analyzed. Mean time between MRI and the following RE was 17 ± 31 days. Median OS after RE was 178 days. Patients with low FFMA had significantly shortened OS compared to patients with high FFMA (median OS: 128 vs. 273 days, p = 0.017). On multivariate Cox regression analysis, OS was best predicted by FFMA (hazard ratio (HR) 2.652; p < 0.001). Baseline bilirubin (HR 1.875; p = 0.030), pattern of tumor manifestation (HR 1.679; p = 0.001), and model of endstage liver disease (MELD) score (HR 1.164; p < 0.001) were also significantly associated with OS. CONCLUSIONS: FFMA was associated with OS in patients receiving RE for treatment of mCRC and might be a new prognostic biomarker for survival prognosis. KEY POINTS: • Fat-free muscle area (FFMA) as a measure of lean muscle area predicts survival in metastatic colorectal liver cancer following radioembolization. • FFMA can easily be assessed from routine pre-interventional liver magnetic resonance imaging. • FFMA might be a new promising biomarker for assessment of sarcopenia.
OBJECTIVES: To investigate the clinical potential of fat-free muscle area (FFMA) to predict outcome in patients with liver-predominant metastatic colorectal cancer (mCRC) undergoing radioembolization (RE) with 90Yttrium microspheres. METHODS:Patients with mCRC who underwent RE in our center were included in this retrospective study. All patients received liver magnetic resonance imaging including standard T2-weighted images. The total erector spinae muscle area and the intramuscular adipose tissue area were measured at the level of the origin of the superior mesenteric artery and subtracted to calculate FFMA. Cutoff values for definition of low FFMA were 3644 mm2 in men and 2825 mm2 in women. The main outcome was overall survival (OS). For survival analysis, the Kaplan-Meier method and Cox regressions comparing various clinic-oncological parameters which potentially may affect OS were performed. RESULTS: Seventy-seven patients (28 female, mean age 60 ± 11 years) were analyzed. Mean time between MRI and the following RE was 17 ± 31 days. Median OS after RE was 178 days. Patients with low FFMA had significantly shortened OS compared to patients with high FFMA (median OS: 128 vs. 273 days, p = 0.017). On multivariate Cox regression analysis, OS was best predicted by FFMA (hazard ratio (HR) 2.652; p < 0.001). Baseline bilirubin (HR 1.875; p = 0.030), pattern of tumor manifestation (HR 1.679; p = 0.001), and model of endstage liver disease (MELD) score (HR 1.164; p < 0.001) were also significantly associated with OS. CONCLUSIONS: FFMA was associated with OS in patients receiving RE for treatment of mCRC and might be a new prognostic biomarker for survival prognosis. KEY POINTS: • Fat-free muscle area (FFMA) as a measure of lean muscle area predicts survival in metastatic colorectal liver cancer following radioembolization. • FFMA can easily be assessed from routine pre-interventional liver magnetic resonance imaging. • FFMA might be a new promising biomarker for assessment of sarcopenia.
Entities:
Keywords:
Brachytherapy; Colorectal cancer; Magnetic resonance imaging; Sarcopenia
Authors: Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Robert J Lewandowski; Kenneth G Thurston; James E Goin; Ching-Yee O Wong; Vanessa L Gates; Mark Van Buskirk; Jean-Francois H Geschwind; Riad Salem Journal: J Vasc Interv Radiol Date: 2005-12 Impact factor: 3.464
Authors: Peter D Peng; Mark G van Vledder; Susan Tsai; Mechteld C de Jong; Martin Makary; Julie Ng; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Michael A Choti; Ihab Kamel; Timothy M Pawlik Journal: HPB (Oxford) Date: 2011-03-29 Impact factor: 3.647
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: Brian L Dunfee; Ahsun Riaz; Robert J Lewandowski; Saad Ibrahim; Mary F Mulcahy; Robert K Ryu; Bassel Atassi; Kent T Sato; Steven Newman; Reed A Omary; Al Benson; Riad Salem Journal: J Vasc Interv Radiol Date: 2009-11-25 Impact factor: 3.464
Authors: Kamyar Kalantar-Zadeh; Tamara B Horwich; Antigone Oreopoulos; Csaba P Kovesdy; Houman Younessi; Stefan D Anker; John E Morley Journal: Curr Opin Clin Nutr Metab Care Date: 2007-07 Impact factor: 4.294
Authors: Sven H Loosen; Maximilian Schulze-Hagen; Tobias Püngel; Lukas Bündgens; Theresa Wirtz; Jakob N Kather; Mihael Vucur; Pia Paffenholz; Münevver Demir; Philipp Bruners; Christiane Kuhl; Christian Trautwein; Frank Tacke; Tom Luedde; Alexander Koch; Christoph Roderburg Journal: Crit Care Explor Date: 2020-08-05
Authors: Anton Faron; Jasmin Abu-Omar; Johannes Chang; Nina Böhling; Alois Martin Sprinkart; Ulrike Attenberger; Jürgen K Rockstroh; Andreas Minh Luu; Christian Jansen; Christian P Strassburg; Jonel Trebicka; Julian Luetkens; Michael Praktiknjo Journal: Front Med (Lausanne) Date: 2022-04-12
Authors: Andre E Modesto; Charlotte E Stuart; Jaelim Cho; Juyeon Ko; Ruma G Singh; Maxim S Petrov Journal: Eur Radiol Date: 2020-02-10 Impact factor: 5.315
Authors: Anton Faron; Stefan Kreyer; Alois M Sprinkart; Thomas Muders; Stefan F Ehrentraut; Alexander Isaak; Rolf Fimmers; Claus C Pieper; Daniel Kuetting; Jens-Christian Schewe; Ulrike Attenberger; Christian Putensen; Julian A Luetkens Journal: Sci Rep Date: 2020-12-28 Impact factor: 4.379
Authors: Anton Faron; Nikola S Opheys; Sebastian Nowak; Alois M Sprinkart; Alexander Isaak; Maike Theis; Narine Mesropyan; Christoph Endler; Judith Sirokay; Claus C Pieper; Daniel Kuetting; Ulrike Attenberger; Jennifer Landsberg; Julian A Luetkens Journal: Diagnostics (Basel) Date: 2021-12-09